Moonlake Immunotherapeutics - Class A (MLTX) closed at $12.87 on November 12, 2026, down 4.7% from the previous close, on volume of 1,419,142 shares (30-day average 1,690,135).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Put Spread | 20-Nov-2610 : 11 P | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
MoonLake Analyst Maintains $50 Price Target on Sonelokimab Regulatory and Pipeline Catalysts
TipRanks (Mon, 9-Nov 6:55 AM ET)
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Market Chameleon (Mon, 10-Aug 3:53 AM ET)
Market Chameleon (Mon, 22-Jun 3:06 AM ET)
Market Chameleon (Mon, 11-May 3:07 AM ET)
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Moonlake Immunotherapeutics - Class A trades on the NASDAQ stock market under the symbol MLTX.
As of November 13, 2026, MLTX stock price declined to $12.56 with 364,755 million shares trading.
MLTX has a beta of 1.21, meaning it tends to be more sensitive to market movements. MLTX has a correlation of 0.04 to the broad based SPY ETF.
MLTX has a market cap of $1.07 billion. This is considered a Small Cap stock.
In the last 3 years, MLTX traded as high as $64.98 and as low as $5.95.
The top ETF exchange traded funds that MLTX belongs to (by Net Assets): TCAF, VHT, ESML, NUSC, GWX.
MLTX has underperformed the market in the last year with a return of -1.6%, while the SPY ETF gained +11.4%. In the last 3 month period, MLTX fell short of the market, returning -27.1%, while SPY returned -2.2%. However, in the most recent 2 weeks MLTX has outperformed the stock market by returning -0.1%, while SPY returned -2.1%.
MLTX support price is $12.26 and resistance is $13.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLTX shares will trade within this expected range on the day.
